BRPI0519030A2 - mÉtodos de tratamento, prevenÇço, ou controle de inflamaÇço das vias aÉreas e de uma doenÇa ou distérbio das vias aÉreas ou pulmonar, e, composiÇço farmacÊutica - Google Patents
mÉtodos de tratamento, prevenÇço, ou controle de inflamaÇço das vias aÉreas e de uma doenÇa ou distérbio das vias aÉreas ou pulmonar, e, composiÇço farmacÊuticaInfo
- Publication number
- BRPI0519030A2 BRPI0519030A2 BRPI0519030-4A BRPI0519030A BRPI0519030A2 BR PI0519030 A2 BRPI0519030 A2 BR PI0519030A2 BR PI0519030 A BRPI0519030 A BR PI0519030A BR PI0519030 A2 BRPI0519030 A2 BR PI0519030A2
- Authority
- BR
- Brazil
- Prior art keywords
- airways
- methods
- lungs
- disease
- pharmaceutical composition
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 5
- 201000010099 disease Diseases 0.000 title abstract 3
- 210000004072 lung Anatomy 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 206010061218 Inflammation Diseases 0.000 title abstract 2
- 208000035475 disorder Diseases 0.000 title abstract 2
- 230000004054 inflammatory process Effects 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 101100296720 Dictyostelium discoideum Pde4 gene Proteins 0.000 abstract 1
- 101100082610 Plasmodium falciparum (isolate 3D7) PDEdelta gene Proteins 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 208000037883 airway inflammation Diseases 0.000 abstract 1
- 238000011443 conventional therapy Methods 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63498204P | 2004-12-13 | 2004-12-13 | |
| PCT/US2005/045071 WO2006065814A1 (en) | 2004-12-13 | 2005-12-12 | Compositions comprising pde4 modulators and their use for the treatment or prevention of airway inflammation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0519030A2 true BRPI0519030A2 (pt) | 2008-12-23 |
Family
ID=36121316
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0519030-4A BRPI0519030A2 (pt) | 2004-12-13 | 2005-12-12 | mÉtodos de tratamento, prevenÇço, ou controle de inflamaÇço das vias aÉreas e de uma doenÇa ou distérbio das vias aÉreas ou pulmonar, e, composiÇço farmacÊutica |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20060148882A1 (enExample) |
| EP (1) | EP1838294A1 (enExample) |
| JP (1) | JP2008523102A (enExample) |
| KR (1) | KR20070092276A (enExample) |
| CN (1) | CN101111235A (enExample) |
| AR (1) | AR052047A1 (enExample) |
| AU (1) | AU2005316593A1 (enExample) |
| BR (1) | BRPI0519030A2 (enExample) |
| CA (1) | CA2590903A1 (enExample) |
| IL (1) | IL183858A0 (enExample) |
| MX (1) | MX2007006992A (enExample) |
| WO (1) | WO2006065814A1 (enExample) |
| ZA (1) | ZA200705540B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050100529A1 (en) * | 2003-11-06 | 2005-05-12 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders |
| KR20070007945A (ko) * | 2004-04-23 | 2007-01-16 | 셀진 코포레이션 | 폐 고혈압증의 치료 및 관리를 위한 ｐｄｅ4 조절인자의사용 방법 및 그를 포함하는 조성물 |
| AU2006305620A1 (en) * | 2005-10-19 | 2007-04-26 | Ranbaxy Laboratories Limited | Compositions of phosphodiesterase type IV inhibitors |
| KR20110116049A (ko) * | 2009-02-10 | 2011-10-24 | 셀진 코포레이션 | 결핵의 치료, 예방 및 관리를 위한 ｐｄｅ4 조절제를 포함하는 조성물 및 사용 방법 |
| MX2011012122A (es) | 2009-05-14 | 2012-02-28 | Tianjin Hemay Bio Tech Co Ltd | Derivados de tiofeno. |
| MX341050B (es) | 2010-04-07 | 2016-08-05 | Celgene Corp * | Metodos para tratar infeccion viral respiratoria. |
| US20140018404A1 (en) | 2010-12-16 | 2014-01-16 | Celgene Corporation | Controlled release oral dosage forms of poorly soluble drugs and uses thereof |
| CN103402980B (zh) * | 2011-01-10 | 2016-06-29 | 细胞基因公司 | 作为pde4和/或细胞因子抑制剂的苯乙基砜异吲哚啉衍生物 |
| WO2012096859A2 (en) * | 2011-01-10 | 2012-07-19 | Celgene Corporation | Oral dosage forms of cyclopropanecarboxylic acid {2-[(1s)-1-(3-ethoxy-4-methoxy-phenyl]-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1h-isoindol-4-yl}-amide |
| EP2683376B1 (en) | 2011-03-07 | 2018-11-28 | Celgene Corporation | Methods for treating diseases using isoindoline compounds |
| KR101889757B1 (ko) | 2011-04-28 | 2018-08-20 | 셀진 코포레이션 | 자가 면역 및 염증 질환의 치료 및 관리를 위한 ｐｄｅ4 저해제를 이용한 방법 및 조성물 |
| WO2014151180A1 (en) | 2013-03-14 | 2014-09-25 | Celgene Corporation | Treatment of psoriatic arthritis using apremilast |
| EP3096749B1 (en) * | 2014-01-24 | 2019-05-15 | Celgene Corporation | Methods for the treatment of obesity using apremilast |
| EP3188745A1 (en) | 2014-08-15 | 2017-07-12 | Celgene Corporation | Dosage titration of apremilast for the treatment of diseases ameliorated by pde4 inhibition |
| US10011611B2 (en) | 2015-08-14 | 2018-07-03 | Reaction Biology Corp. | Histone deacetylase inhibitors and methods for use thereof |
| CA3034785C (en) * | 2016-08-22 | 2022-11-15 | Shijiazhuang Sagacity New Drug Development Co., Ltd. | Pde4 inhibitor |
| DK3590924T3 (da) * | 2017-02-28 | 2022-01-03 | Kangpu Biopharmaceuticals Inc | Hidtil ukendt isoindolinderivat og farmaceutisk sammensætning og anvendelse deraf |
| WO2018167142A1 (en) * | 2017-03-16 | 2018-09-20 | Takeda Gmbh | Treatment of idiopathic pulmonary fibrosis |
| GB202306663D0 (en) | 2023-05-05 | 2023-06-21 | Union Therapeutics As | Combination therapy |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6020358A (en) * | 1998-10-30 | 2000-02-01 | Celgene Corporation | Substituted phenethylsulfones and method of reducing TNFα levels |
| US6667316B1 (en) * | 1999-11-12 | 2003-12-23 | Celgene Corporation | Pharmaceutically active isoindoline derivatives |
| US6699899B1 (en) * | 1999-12-21 | 2004-03-02 | Celgene Corporation | Substituted acylhydroxamic acids and method of reducing TNFα levels |
| US6962940B2 (en) * | 2002-03-20 | 2005-11-08 | Celgene Corporation | (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
| US7276529B2 (en) * | 2002-03-20 | 2007-10-02 | Celgene Corporation | Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
| US7354948B2 (en) * | 2002-11-06 | 2008-04-08 | Celgene Corporation | Methods for treatment of chronic uveitis using cyclopropyl-n-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide |
| AU2003294311B8 (en) * | 2002-11-18 | 2008-06-05 | Celgene Corporation | Method of using and compositions comprising (+)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide |
| CA2511843C (en) * | 2002-12-30 | 2012-04-24 | Celgene Corporation | Fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds and their pharmaceutical uses |
| KR20070007945A (ko) * | 2004-04-23 | 2007-01-16 | 셀진 코포레이션 | 폐 고혈압증의 치료 및 관리를 위한 ｐｄｅ4 조절인자의사용 방법 및 그를 포함하는 조성물 |
| US20080267905A1 (en) * | 2004-05-05 | 2008-10-30 | Celgene Corporation | Methods and Compositions Using Selective Cytokine Inhibitory Drugs for Treatment and Management of Cancers and Other Diseases |
| US7244759B2 (en) * | 2004-07-28 | 2007-07-17 | Celgene Corporation | Isoindoline compounds and methods of making and using the same |
-
2005
- 2005-12-12 BR BRPI0519030-4A patent/BRPI0519030A2/pt not_active IP Right Cessation
- 2005-12-12 EP EP05853888A patent/EP1838294A1/en not_active Withdrawn
- 2005-12-12 WO PCT/US2005/045071 patent/WO2006065814A1/en not_active Ceased
- 2005-12-12 AU AU2005316593A patent/AU2005316593A1/en not_active Abandoned
- 2005-12-12 KR KR1020077015958A patent/KR20070092276A/ko not_active Withdrawn
- 2005-12-12 JP JP2007545718A patent/JP2008523102A/ja not_active Abandoned
- 2005-12-12 MX MX2007006992A patent/MX2007006992A/es unknown
- 2005-12-12 CN CNA2005800476591A patent/CN101111235A/zh active Pending
- 2005-12-12 CA CA002590903A patent/CA2590903A1/en not_active Abandoned
- 2005-12-12 ZA ZA200705540A patent/ZA200705540B/xx unknown
- 2005-12-13 AR ARP050105222A patent/AR052047A1/es not_active Application Discontinuation
- 2005-12-13 US US11/299,702 patent/US20060148882A1/en not_active Abandoned
-
2007
- 2007-06-12 IL IL183858A patent/IL183858A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL183858A0 (en) | 2007-10-31 |
| AR052047A1 (es) | 2007-02-28 |
| ZA200705540B (en) | 2009-01-28 |
| CN101111235A (zh) | 2008-01-23 |
| AU2005316593A1 (en) | 2006-06-22 |
| US20060148882A1 (en) | 2006-07-06 |
| CA2590903A1 (en) | 2006-06-22 |
| JP2008523102A (ja) | 2008-07-03 |
| WO2006065814A1 (en) | 2006-06-22 |
| MX2007006992A (es) | 2007-08-03 |
| EP1838294A1 (en) | 2007-10-03 |
| KR20070092276A (ko) | 2007-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0519030A2 (pt) | mÉtodos de tratamento, prevenÇço, ou controle de inflamaÇço das vias aÉreas e de uma doenÇa ou distérbio das vias aÉreas ou pulmonar, e, composiÇço farmacÊutica | |
| JP6099609B2 (ja) | 肺炎症を低減するためのレボフロキサシンの吸入 | |
| BRPI0416260A (pt) | método para tratar, prevenir ou controlar uma doença ou distúrbio relacionada com amianto, e, composição farmacêutica | |
| BR0316050A (pt) | Métodos de tratar, controlar ou prevenir um câncer especìfico e doença associada com angiogênese indesejada e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo e com terapia de radiação, terapia hormonal, terapia biológica, ou imunoterapia em um paciente sofrendo de um câncer especìfico, composição farmacêutica e kit | |
| BRPI0509400A (pt) | métodos para tratar ou prevenir sono disfuncional, para controlar sono disfuncional e para melhorar o tempo para o começo do sono, a duração do sono ou a qualidade do sono ou realçar a capacidade para levantar sentindo-se renovado depois de um sono noturno, composição farmacêutica, e, kit adequado para o uso no tratamento, prevenção ou controle de sono disfuncional | |
| BRPI0415649A (pt) | método para tratar, prevenir, modificar ou administrar dor, e, composição farmacêutica | |
| BR0316082A (pt) | Métodos de tratar ou prevenir e de controlar uma doença mieloproliferative, de reduzir ou evitar um efeito adverso associado com a administração de um segundo agente ativo em um paciente sofrendo de uma doença mieloproliferativa e de aumentar a eficácia terapêutica de um tratamento de doenças mieloproliferativa, composição farmacêutica e kit | |
| BRPI0410306A (pt) | métodos para tratar, controlar ou evitar um cáncer especìfico, para tratar, controlar ou evitar uma doença associada com angiogênese indesejada e para reduzir ou evitar um efeito adverso, composição farmacêutica, e, kit | |
| BRPI0507966A (pt) | uso de meloxicam para o tratamento de doenças respiratórias em porcos | |
| BRPI0517481A (pt) | método para tratar, controlar ou evitar uma doença ou distúrbio parasìtico protozoário, e, composição farmacêutica | |
| BR0316057A (pt) | Métodos de tratar, controlar ou prevenir um câncer especìfico e uma doença associada com angiogênese indesejada e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo e com a terapia de radiação, terapia hormonal, terapia biológica ou imunoterapia em um paciente sofrendo de um câncer especìfico, composição farmacêutica e kit | |
| RU2007130700A (ru) | Комбинация соединений метилксантина и стероидов для лечения хронических распираторных заболеваний | |
| BRPI0515600A (pt) | formas farmacêuticas opióides tendo cmédia e auc em estado estável proporcionais à dose e cmax de dose única inferior ao proporcional à dose | |
| BRPI0416275A (pt) | métodos de tratar, controlar ou prevenir um cáncer especìfico e uma doença associada com angiogênese indesejada | |
| BR0315573A (pt) | Método para tratar, prevenir, controlar e/ou modificar dor em um paciente e composição farmacêutica | |
| BR0315593A (pt) | Método de tratar, prevenir, modificar ou controlar dor e composição farmacêutica | |
| BRPI0510166A (pt) | método para tratar, prevenir ou controlar hipertensão pulmonar, e, composição farmacêutica | |
| RU2008152341A (ru) | Применение аллопуринола для лечения ладонно-подошвенной эритродизестезии | |
| BR0315316A (pt) | Métodos de tratar, prevenir ou controlar uma sìndrome mielodisplásica, e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de uma sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária, e, kit | |
| WO2007123848A3 (en) | Therapeutic compositions containing modified class i slrp proteins | |
| BR0206300A (pt) | composição farmacêutica para tratar distúrbio urinário em um mamìfero e uso | |
| BRPI0415651A (pt) | métodos para tratar, prevenir, modificar e/ou administrar fibromialgia, e para reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de fibromialgia, e, composição farmacêutica | |
| BR0315931A (pt) | Método de tratar, prevenir ou controlar degeneração macular e composição farmacêutica | |
| BRPI0418801A (pt) | métodos de tratamento, controle ou prevenção de um cáncer especìfico, e de uma doença associada com angiogênese indesejada, de redução ou prevenção de um efeito adverso, composição farmacêutica, e, kit | |
| BRPI0510167A (pt) | método para tratar, prevenir ou controlar hipertensão pulmonar |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A E 6A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012. |